Bragar Eagel & Squire Sues Major Corporations for Investor Misconduct
New York, Wednesday, 2 April 2025.
Bragar Eagel & Squire has filed class action lawsuits against key firms, potentially affecting stock prices and investor confidence. Affected investors are encouraged to contact the firm.
Multiple Companies Face Legal Scrutiny
In a significant development for investor protection, Bragar Eagel & Squire, P.C. has initiated class action lawsuits against several prominent companies including XPLR Infrastructure, LP (NYSE:XIFR), Geron Corporation (NASDAQ: GERN), enCore Energy Corp. (NASDAQ: EU), and Fluence Energy, Inc. (NASDAQ: FLNC) [1]. The legal actions, announced on April 1, 2025, highlight alleged violations of securities laws and misleading statements that potentially impacted investor decisions.
Critical Allegations and Deadlines
Each case presents distinct allegations of corporate misconduct. XPLR Infrastructure faces accusations of making materially false and misleading statements about its business operations, with a lead plaintiff deadline of May 9, 2025 [1]. Geron Corporation’s lawsuit centers on allegations regarding material misrepresentations about its drug Rytelo (imetelstat), including misleading statements about its commercial potential and market position, with investors having until May 12, 2025, to join the action [1]. enCore Energy Corp. is accused of false statements and material omissions regarding its business operations, with a May 13, 2025 deadline [1].
Recent Additions to Legal Portfolio
The firm has expanded its legal actions to include additional corporations. On March 31, 2025, a separate class action was filed against Actinium Pharmaceuticals, Inc. (NYSE: ATNM), concerning alleged false statements about FDA submissions between October 31, 2022, and August 2, 2024 [2]. Similarly, SoundHound AI, Inc. (NASDAQ:SOUN) faces litigation regarding financial reporting deficiencies, with the complaint filed in the Northern District of California [6]. SoundHound’s stock experienced a significant decline of $0.61 per share (5.86%) to $9.72 following disclosures about reporting delays [6].